A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure Therapy and Living With Overweight or Obesity (MARITIME-OSA-2)
Latest Information Update: 08 Mar 2026
At a glance
- Drugs Maridebart cafraglutide (Primary)
- Indications Sleep apnoea syndrome
- Focus Registrational; Therapeutic Use
- Acronyms MARITIME-OSA-2
- Sponsors Amgen
Most Recent Events
- 24 Nov 2025 Status changed from not yet recruiting to recruiting.
- 13 Nov 2025 New trial record